Results 211 to 220 of about 257,742 (291)

A real-world retrospective cohort study comparing brand-name febuxostat (feburic) and generic febuxostat (feuri). [PDF]

Sci Prog
Tsai SF, Wu MJ, Chen CH.
europepmc   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

An integrated analysis of naval platform survivability for mission resilience. [PDF]

Sci Rep
Woolley A, Gargano A, Aksu S, Gamble G, Foos D.   +4 more
europepmc   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Cardiovascular risk equations in type 1 diabetes: from generic models to personalized prediction. [PDF]

Ann Med
Serés-Noriega T, Aguilo-Lafarga I, Perea V, Viñals C, Amor AJ.   +4 more
europepmc   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source

The need for a unique ICD-10-CM code for acid attack survivors. [PDF]

Proc (Bayl Univ Med Cent)
Kapur KD, Verma S, Kapur S, Nguyen KT, Friedmann DP, Verma KK, Tarbox MB.   +6 more
europepmc   +1 more source

A New Strategy to Design Reconfigurable Rivest–Shamir–Adleman (RSA) Accelerators

International Journal of Circuit Theory and Applications, EarlyView.
A reconfigurable FPGA‐based RSA accelerator is proposed using compression‐based modular multipliers combined with pseudomoduli arithmetic. The approach maps modular exponentiation to low‐cost arithmetic domains and applies a correction stage, achieving significant improvements in delay, operating frequency, and delay–area efficiency compared with ...
Augusto C. B. Vassoler, Gabriel B. M. Fernandes, Lucas R. Kieslich, Eduardo A. Bezerra, Hector Pettenghi   +4 more
wiley   +1 more source

A Program‐Led Motivational App (MI‐Coach: ED) for Eating Disorder Waitlists: Findings From a Feasibility and Acceptability Pilot Trial

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Individuals with eating disorders (EDs) often face significant barriers to accessing care, including prolonged waitlists and systemic delays. Digital interventions, such as mobile apps, offer a scalable way to enhance pre‐treatment engagement during this high‐risk period.
Amané Halicki‐Asakawa, Emily Fuller, Maya Libben   +2 more
wiley   +1 more source

The plasmid-host fitness landscape: a new paradigm for predicting the fate of mobile resistance. [PDF]

Appl Environ Microbiol
Abdulqadir HN.
europepmc   +1 more source